目次

TABLE OF CONTENTS

1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 MARKET SCOPE
1.3.1 STUDY INCLUSIONS AND EXCLUSIONS
1.3.2 MARKETS COVERED
1.3.3 YEARS CONSIDERED FOR STUDY
1.4 CURRENCY CONSIDERED
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
2.1.2.1 Key data from primary sources
2.1.2.2 Key industry insights
2.2 MARKET SIZE ESTIMATION
2.3 DATA TRIANGULATION
2.4 MARKET SHARE ESTIMATION
2.5 ASSUMPTIONS FOR STUDY
2.6 RESEARCH LIMITATIONS
2.6.1 SCOPE-RELATED LIMITATIONS
2.6.2 METHODOLOGY-RELATED LIMITATIONS
2.7 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS
4.1 INSULIN DELIVERY DEVICES: MARKET OVERVIEW
4.2 NORTH AMERICA: INSULIN DELIVERY DEVICES MARKET, BY TYPE AND COUNTRY
4.3 INSULIN DELIVERY DEVICES MARKET: GEOGRAPHICAL MIX
4.4 INSULIN DELIVERY DEVICES MARKET: REGIONAL MIX
4.5 INSULIN DELIVERY DEVICES MARKET: DEVELOPED VS. DEVELOPING MARKETS

5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Growth in prevalence of diabetic population
5.2.1.2 Technological advancements in insulin delivery devices
5.2.1.3 Government support and favorable reimbursement schemes to favor the market growth
5.2.2 RESTRAINTS
5.2.2.1 High cost and lack of reimbursement in emerging economies
5.2.2.2 Needle anxiety in patients to affect growth of pen needles and syringes market
5.2.2.3 Oral insulin as alternative drug delivery method
5.2.3 OPPORTUNITIES
5.2.3.1 Increase in research & development activities and strategic partnerships
5.2.3.2 Increase in healthcare expenditure on diabetes care
5.2.3.3 Advances in insulin syringe and needle technology
5.2.3.4 Mandates pertaining to safety-engineered medical needles
5.2.4 CHALLENGES
5.2.4.1 Needlestick injuries and misuse of injection pens
5.2.4.2 Lack of interoperability among insulin delivery devices
5.3 REGULATORY ANALYSIS
5.3.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.3.2 REGULATORY FRAMEWORK
5.3.2.1 North America
5.3.2.1.1 US
5.3.2.1.2 Canada
5.3.2.2 Europe
5.3.2.3 Asia Pacific
5.3.2.3.1 Japan
5.3.2.3.2 China
5.3.2.3.3 India
5.3.2.3.4 Australia
5.3.2.4 Latin America
5.3.2.4.1 Brazil
5.3.2.4.2 Mexico
5.3.2.5 Middle East
5.3.2.6 Africa
5.4 INDUSTRY TRENDS
5.4.1 GROWING DEMAND FOR HYBRID CLOSED-LOOP SYSTEMS/ARTIFICIAL PANCREAS DEVICE SYSTEMS
5.4.2 SYNCHRONIZATION OF SMART INSULIN PENS WITH CONTINUOUS GLUCOSE MONITORING SYSTEMS PROMOTES DIABETES DATA SHARING
5.4.3 INCREASE IN NUMBER OF COLLABORATIONS AMONG STAKEHOLDERS
5.5 REIMBURSEMENT SCENARIO
5.5.1 GLOBAL COVERAGE AND REIMBURSEMENT
5.6 TECHNOLOGY ANALYSIS
5.7 TECHNOLOGY ANALYSIS
5.7.1 KEY TECHNOLOGIES
5.7.1.1 Automated insulin delivery
5.7.2 COMPLEMENTARY TECHNOLOGIES
5.7.2.1 Bluetooth
5.7.3 ADJACENT TECHNOLOGIES
5.7.3.1 Continuous glucose monitoring
5.8 KEY CONFERENCES & EVENTS
5.9 PRICING ANALYSIS
5.9.1 INDICATIVE PRICING TREND OF INSULIN DELIVERY DEVICE, BY KEY PLAYER
5.9.2 INDICATIVE PRICING TREND OF INSULIN DELIVERY DEVICE, BY REGION
5.10 TRADE ANALYSIS
5.11 PATENT ANALYSIS
5.11.1 PATENT PUBLICATION TRENDS FOR INSULIN DELIVERY DEVICES
5.11.2 JURISDICTION ANALYSIS: TOP APPLICANTS FOR PATENTS IN INSULIN DELIVERY DEVICES MARKET
5.12 SUPPLY CHAIN ANALYSIS
5.13 VALUE CHAIN ANALYSIS
5.14 ECOSYSTEM MARKET MAP
5.15 CASE STUDY ANALYSIS
5.15.1 OMNIPOD 5 FACILITATED EFFECTIVE INSULIN MANAGEMENT FOR YOUNG ATHLETES, SUPPORTING CONTINUITY IN TRAINING AND COMPETITION
5.15.2 MEDTRONIC MINIMED INSULIN PUMP ENHANCED GLUCOSE CONTROL, IMPROVING DAILY MANAGEMENT FOR PEOPLE WITH DIABETES
5.15.3 SMART INSULIN DELIVERY WITH MEDTRONIC INPEN FOR IMPROVED DIABETES MANAGEMENT
5.16 PORTER'S FIVE FORCES ANALYSIS
5.16.1 INTENSITY OF COMPETITIVE RIVALRY
5.16.2 BARGAINING POWER OF SUPPLIERS
5.16.3 BARGAINING POWER OF BUYERS
5.16.4 THREAT OF SUBSTITUTES
5.16.5 THREAT OF NEW ENTRANTS
5.17 KEY STAKEHOLDERS AND BUYING CRITERIA
5.17.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.17.2 BUYING CRITERIA
5.18 ADJACENT MARKET ANALYSIS
5.19 INVESTMENT & FUNDING SCENARIO
5.20 UNMET NEEDS/END-USER EXPECTATIONS IN INSULIN DELIVERY DEVICES MARKET
5.21 TRENDS/DISRUPTION IMPACTING CUSTOMER'S BUSINESS
5.22 IMPACT OF AI/GENERATIVE AI ON INSULIN DELIVERY DEVICES MARKET

6 INSULIN DELIVERY DEVICES MARKET, BY TYPE
6.1 INTRODUCTION
6.2 INSULIN PENS
6.2.1 ADVANCED AND CONVENIENT SOLUTIONS FOR INSULIN ADMINISTRATION TO DRIVE MARKET
6.2.2 REUSABLE INSULIN PENS
6.2.2.1 Technology innovations offering cost-effectiveness to boost growth
6.2.3 DISPOSABLE INSULIN PENS
6.2.3.1 Ease of use to drive market, though shift toward eco-friendly environment can challenge growth
6.3 INSULIN PUMPS
6.3.1 PRECISION OFFERED BY NEWER AND MORE REFINED TECHNOLOGY TO DRIVE INSULIN PUMPS MARKET
6.3.2 TETHERED INSULIN PUMPS
6.3.2.1 Increase in collaborations and partnerships between companies to develop integrated CGM systems to drive market
6.3.3 TUBELESS INSULIN PUMPS
6.3.3.1 Use of artificial intelligence and technological advancements to boost market
6.4 INSULIN PEN NEEDLES
6.4.1 STANDARD INSULIN PEN NEEDLES
6.4.1.1 Affordability of standard insulin pen needles over safety pen needles to propel growth
6.4.2 SAFETY INSULIN PEN NEEDLES
6.4.2.1 Reduced chances of infection and accidental pricking to drive market
6.5 INSULIN SYRINGES
6.5.1 COMMONLY USED DELIVERY MEANS CHALLENGED BY SAFETY CONCERNS AND AWARENESS OF AFFORDABLE ALTERNATIVES
6.6 OTHER INSULIN DELIVERY DEVICES

7 INSULIN DELIVERY DEVICES MARKET, BY DISEASE TYPE
7.1 INTRODUCTION
7.2 TYPE 1 DIABETES
7.2.1 CHRONIC NATURE OF TYPE 1 DIABETES, COMBINED WITH SIGNIFICANT INCIDENCE IN CHILDREN AND YOUNG ADULTS, TO DRIVE GROWTH
7.3 TYPE 2 DIABETES
7.3.1 RISING PREVALENCE OF TYPE 2 DIABETES, DRIVEN BY LIFESTYLE-RELATED RISK FACTORS AND EARLIER DISEASE ONSET TO FUEL MARKET

8 INSULIN DELIVERY DEVICES MARKET, BY END USER
8.1 INTRODUCTION
8.2 HOME CARE SETTINGS
8.2.1 INCREASE IN AFFORDABILITY OF SELF-MONITORING SYSTEMS AND INSULIN DELIVERY DEVICES TO FUEL SELF/HOME HEALTHCARE
8.3 HOSPITALS & CLINICS
8.3.1 RISE IN DEMAND FOR POINT-OF-CARE TESTING IN HOSPITALS TO BOOST MARKET GROWTH
8.4 OTHER END USERS

9 INSULIN DELIVERY DEVICES MARKET, BY REGION
9.1 INTRODUCTION
9.2 NORTH AMERICA
9.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
9.2.2 US
9.2.2.1 Largest share of North American insulin delivery device market
9.2.3 CANADA
9.2.3.1 Rise in government support to boost market in Canada
9.3 EUROPE
9.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
9.3.2 GERMANY
9.3.2.1 Germany to dominate European insulin delivery devices market
9.3.3 UK
9.3.3.1 Government support and research funding to drive market growth in UK
9.3.4 FRANCE
9.3.4.1 High insurance coverage and increasing affordability to fuel market
9.3.5 ITALY
9.3.5.1 Increase in government spending to drive insulin delivery device growth in Italy
9.3.6 SPAIN
9.3.6.1 Minimal co-payments and full reimbursement to drive market growth in Spain
9.3.7 REST OF EUROPE (ROE)
9.4 ASIA PACIFIC
9.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
9.4.2 CHINA
9.4.2.1 China to dominate Asia Pacific's insulin delivery devices market
9.4.3 JAPAN
9.4.3.1 Rise in aging population and high diabetes cases to drive growth in Japan
9.4.4 INDIA
9.4.4.1 Rise in diabetes cases and affordable local manufacturing to fuel insulin device demand in India
9.4.5 AUSTRALIA
9.4.5.1 Government subsidies to support market growth
9.4.6 SOUTH KOREA
9.4.6.1 Rise in diabetes cases and strong government healthcare support to boost market
9.4.7 REST OF ASIA PACIFIC
9.5 LATIN AMERICA
9.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
9.5.2 BRAZIL
9.5.2.1 Brazil to account for largest share in Latin American insulin delivery devices market
9.5.3 MEXICO
9.5.3.1 Growth in regulatory support to propel market
9.5.4 REST OF LATIN AMERICA
9.6 MIDDLE EAST & AFRICA
9.6.1 MACROECONOMIC OUTLOOK FOR THE MIDDLE EAST & AFRICA
9.6.2 GCC COUNTRIES
9.6.2.1 Rise in diabetes prevalence and high per capita healthcare expenditure to drive market in GCC countries
9.6.3 REST OF THE MIDDLE EAST & AFRICA

10 COMPETITIVE LANDSCAPE
10.1 INTRODUCTION
10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
10.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN INSULIN DELIVERY DEVICES MARKET
10.3 REVENUE ANALYSIS, 2022-2024
10.4 MARKET SHARE ANALYSIS, 2024
10.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
10.5.1 STARS
10.5.2 EMERGING LEADERS
10.5.3 PERVASIVE PLAYERS
10.5.4 PARTICIPANTS
10.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
10.5.5.1 Company footprint
10.5.5.2 Type footprint
10.5.5.3 Region footprint
10.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
10.6.1 PROGRESSIVE COMPANIES
10.6.2 RESPONSIVE COMPANIES
10.6.3 DYNAMIC COMPANIES
10.6.4 STARTING BLOCKS
10.6.5 COMPETITIVE BENCHMARKING
10.6.5.1 DETAILED LIST OF KEY STARTUPS/SMES, 2024
10.6.5.2 COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
10.7 BRAND/PRODUCT COMPARISON
10.8 COMPANY VALUATION & FINANCIAL METRICS
10.8.1 FINANCIAL METRICS
10.8.2 COMPANY VALUATION
10.9 R&D ASSESSMENT OF KEY PLAYERS
10.10 COMPETITIVE SCENARIO
10.10.1 PRODUCT LAUNCHES & APPROVALS
10.10.2 DEALS
10.10.3 EXPANSIONS
10.10.4 OTHER DEVELOPMENTS

11 COMPANY PROFILES
11.1 KEY PLAYERS
11.1.1 EMBECTA CORP. (FORMERLY BECTON, DICKINSON AND COMPANY DIABETES CARE BUSINESS)
11.1.1.1 Business overview
11.1.1.2 Products offered
11.1.1.3 Recent developments
11.1.1.3.1 Product launches and approvals
11.1.1.3.2 Deals
11.1.1.3.3 Expansions
11.1.1.3.4 Other developments
11.1.1.4 MnM view
11.1.1.4.1 Right to win
11.1.1.4.2 Strategic choices
11.1.1.4.3 Weaknesses & competitive threats
11.1.2 NOVO NORDISK A/S
11.1.2.1 Business overview
11.1.2.2 Products offered
11.1.2.3 Recent developments
11.1.2.3.1 Product launches and approvals
11.1.2.3.2 Deals
11.1.2.3.3 Other developments
11.1.2.4 MnM view
11.1.2.4.1 Right to win
11.1.2.4.2 Strategic choices
11.1.2.4.3 Weaknesses & competitive threats
11.1.3 MEDTRONIC
11.1.3.1 Business overview
11.1.3.2 Products offered
11.1.3.3 Recent developments
11.1.3.3.1 Product launches and approvals
11.1.3.3.2 Deals
11.1.3.3.3 Expansions
11.1.3.3.4 Other developments
11.1.3.4 MnM view
11.1.3.4.1 Right to win
11.1.3.4.2 Strategic choices
11.1.3.4.3 Weaknesses & competitive threats
11.1.4 SANOFI
11.1.4.1 Business overview
11.1.4.2 Products offered
11.1.4.3 Recent developments
11.1.4.3.1 Product launches and approvals
11.1.4.3.2 Expansions
11.1.4.3.3 Other developments
11.1.4.4 MnM view
11.1.4.4.1 Right to win
11.1.4.4.2 Strategic choices
11.1.4.4.3 Weaknesses & competitive threats
11.1.5 ELI LILLY AND COMPANY
11.1.5.1 Business overview
11.1.5.2 Products offered
11.1.5.3 Recent developments
11.1.5.3.1 Product launches and approvals
11.1.5.3.2 Deals
11.1.5.3.3 Expansions
11.1.5.3.4 Other developments
11.1.5.4 MnM view
11.1.5.4.1 Right to win
11.1.5.4.2 Strategic choices
11.1.5.4.3 Weaknesses and competitive threats
11.1.6 TANDEM DIABETES CARE, INC.
11.1.6.1 Business overview
11.1.6.2 Products offered
11.1.6.3 Recent developments
11.1.6.3.1 Product launches and approvals
11.1.6.3.2 Deals
11.1.7 INSULET CORPORATION
11.1.7.1 Business overview
11.1.7.2 Products offered
11.1.7.3 Recent developments
11.1.7.3.1 Product launches and approvals
11.1.7.3.2 Deals
11.1.7.3.3 Expansions
11.1.7.3.4 Other developments
11.1.8 BIOCON
11.1.8.1 Business overview
11.1.8.2 Products offered
11.1.8.3 Recent developments
11.1.8.3.1 Deals
11.1.8.3.2 Other developments
11.1.9 ROCHE DIABETES CARE
11.1.9.1 Business overview
11.1.9.2 Products offered
11.1.9.3 Recent developments
11.1.9.3.1 Product launches and approvals
11.1.10 HTL-STREFA (SUBSIDIARY OF THE MTD GROUP)
11.1.10.1 Business overview
11.1.10.2 Products offered
11.1.10.3 Recent developments
11.1.10.3.1 Deals
11.1.11 YPSOMED
11.1.11.1 Business overview
11.1.11.2 Products offered
11.1.11.3 Recent developments
11.1.11.3.1 Product launches and approvals
11.1.11.3.2 Deals
11.1.11.3.3 Expansions
11.1.11.3.4 Other developments
11.1.12 MEDTRUM TECHNOLOGIES INC.
11.1.12.1 Business overview
11.1.12.2 Products offered
11.1.13 TERUMO CORPORATION
11.1.13.1 Business overview
11.1.13.2 Products offered
11.1.13.3 Recent developments
11.1.13.3.1 Product launches and approvals
11.1.13.3.2 Deals
11.1.13.3.3 Expansions
11.1.13.3.4 Other developments
11.1.14 WOCKHARDT LIMITED
11.1.14.1 Business overview
11.1.14.2 Products offered
11.1.14.3 Recent developments
11.1.14.3.1 Product launches and approvals
11.1.14.3.2 Other developments
11.1.15 NIPRO
11.1.15.1 Business overview
11.1.15.2 Products offered
11.1.15.3 Recent developments
11.1.15.3.1 Expansions
11.2 OTHER PLAYERS
11.2.1 CEQUR CORPORATION
11.2.2 EOFLOW CO., LTD.
11.2.3 HINDUSTAN SYRINGES & MEDICAL DEVICES LTD
11.2.4 SOOIL DEVELOPMENTS CO., LTD
11.2.5 SUNGSHIM MEDICAL CO., LTD.
11.2.6 B.BRAUN SE
11.2.7 DEBIOTECH SA
11.2.8 JIANGSU DELFU MEDICAL DEVICE CO., LTD
11.2.9 HASELMEIER (A SUBSIDIARY OF MEDMIX)
11.2.10 MANNKIND CORPORATION

12 APPENDIX
12.1 DISCUSSION GUIDE
12.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
12.3 CUSTOMIZATION OPTIONS
12.4 RELATED REPORTS
12.5 AUTHOR DETAILS